Lhasa Limited shared knowledge shared progress

How to better anticipate and mitigate adverse drug reactions [an infographic]

17 February 2021

Read time: less than 5 minutes

Effiris blog image Feb2021

Are you interested in collaboratively using data to predict and avoid adverse drug reactions? The Effiris consortium - currently composed of Takeda, GSK and UCB - is working to achieve just that.

The project aims to help pharmaceutical organisations accelerate drug discovery through machine learning.

Many readers will be very familiar with the fact that one of the biggest challenges in building accurate predictive models within the pharmaceutical drug discovery space, is the limited availability of high-quality data, due to the often-confidential nature of the data. The Effiris privacy preserving data sharing methodology aims to overcome this obstacle.  

Read more about the Effiris approach and progress in the infographic below.


If you have read this far, you might also be interested in joining our free Effiris webinar on Thursday 18th February - register or catch up here.


Did you enjoy this blog? Please let us know.

What else would you like us to write about? Please let us know.

About this article



    Read Time:

    Clock: less than 5 minutesless than 5 minutes

    Related Products:

    © 2023 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
    VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).